Author:
Gupta Riya,Saxena Naveen,Gupta Parul
Abstract
Background/Aim: Mumps is by vaccine preventable infectious disease characterised by parotitis. In India mumps vaccines are not currently used under National Immunisation Programme (NIP). Waning of vaccine-induced immunity is considered to play a central role in the re-emergence of mumps. The comprehensive data on the seroepidemiology of measles, mumps, and rubella (MMR) as well as studies which compare the antibody titre among mumps vaccine naiveand mumps vaccinated children are lacking. The aim of this study was to estimate and compare mumps specific antibody titre in children with and without MMR vaccine. Methods: In 2019/2020, blood samples were collected from 100 healthy children attending immunisation clinic in Government Medical College Kota and associated J K Lon Maternal and Child care hospital Kota. The samples were investigated for MMR IgG antibodies using ELISA. Results: Out of total 100 children included in the study, 32.27 % vaccinated and 4.83 % non-vaccinated children were positive for mumps IgG antibody in the age group of 6 months to 6 years of age. Children aged 6 to 12 years, vaccinated and non-vaccinated, had 31.57 % and 26.57 % positivity, respectively. The seroprevalence of measles, mumps and rubella antibodies among 50 MMR vaccinated children were 94 %, 64 %, and 96 %, respectively. A high measles and rubella seroprevalences were observed among all children age groups, suggesting an effective control program, while the mumps seroprevalence decreased significantly with age. Conclusion: The maximum vaccine effectiveness against mumps for 2 doses of MMR vaccine is ≈ 96 %. The herd immunity threshold to block mumps virus transmission is ≥ 86 %. In this study only 64 % of the vaccinated children were found to have IgG mumps antibodies. In view of morbidity following mumps infection there is a need to incorporate mumps vaccine along with measles and rubella vaccine in the NIP instead of Mr.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference31 articles.
1. Plotkin SA, Rubin SA. Mumps vaccines. Chapter 40. In: Plotkin SA, Orenstein WA, ed. Vaccines. 7th ed. Philadelpia: Elsevier; 2018;
2. Hatchette TF, Mahony JB, Chong S, LeBlanc JJ. Difficulty with mumps diagnosis: What is the contribution of mumps mimickers? J ClinVirol 2009;46:381-3;
3. World Health Organization. Position paper. Mumps virus vaccines. Wkly Epidemiol Rec 2007;7:51-60;
4. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999;77(1):3-14;
5. Atrasheuskaya AV, Kulak MV, Rubin S, Ignatyev GM. Mumps vaccine investigation in Novosibirsk, Russia, 2002-2004. Clin Microbiol Infect 2007;13:670-6;